Orthocell Limited
(ASX:OCC) has won a US patent for its ‘cell factory’ technology which helps in tissue growth and regeneration.
The new technology promotes tissue specific growth for cartilage and bone active proteins. It has previously been difficult to find a trigger to help isolate the growth in cartilage and bone from other growth factors that exist in the body.
The US sees more than half a million cartilage surgeries each year and Orthocell plans to take advantage of its specific cultivated growth technologies in an area which deeply affects mobility and quality of life.
The patent will last till 2027.
Orthocell made a net loss of $3.74 million in the full year to 30th June 2015.
